The company reported group revenues have climb 9.2% to 311.4 million EUR in Q3 2012, with third quarter adjusted EBITDA margins at 19.5%
Gerresheimer AG, which services the pharma and healthcare industry, is still on course for growth. Gerresheimer has experienced marked growth in revenues in the third quarter of the 2012 financial year (December 1, 2011 to November 30, 2012) of 9.2 percent to EUR 311.4m. At constant exchange rates growth in revenues was 6.3 percent. All divisions contributed to this positive development.
Gerresheimer’s operating result (adjusted EBITDA) was 60.8 million EUR in the third quarter of 2012, which is 3.7 million EUR or 6.5% higher than the figure for the same quarter of 2011. The adjusted EBITDA margin was 19.5% in the third quarter (prior year 20.0%). Net income declined due to one-off effects to 14.4 million EUR, which is 4.8 million EUR lower than the prior year quarter’s figure. Third quarter earnings per share of 0.62 EUR were 0.08 EUR, slightly lower than one year ago.
Gerresheimer expects the growth of revenues in the financial year 2012 to be unchanged at 9 to 10% at constant exchange rates. The adjusted EBITDA margin forecast also remains the same at 19.5%. The company is still expecting the investment volume in the financial year 2012 to be around 120 million.